Product Overview
[Drug Name]
Generic Name: Metoprolol Succinate Sustained-Release Tablets
Trade Name: Heyuan/Jiechun Metoprolol Succinate Sustained-Release Tablets, 47.5mg*28 Tablets
Pinyin Code: HeYuan/JieChun ZuoZuoSuanMeiTuoLuoErHuanShiPian, 47.5mg*28 Tablets
[Main Ingredient]
The main ingredient of this product is metoprolol succinate. Chemical Name: 1-Isopropylamino-3-[p-(2-methoxyethyl)phenoxy]-2-propanol L(+)-succinate. Molecular Formula: (C₁₅H₂₅NO₃)₂•C₄H₆O₄. Molecular Weight: 652.82
[Properties]
This product is a film-coated tablet that appears white or off-white after removal of the coating.
[Indications/Main Functions]
Hypertension. Angina pectoris. Stable chronic heart failure with symptoms of left ventricular systolic dysfunction.
[Precautions]
See package insert for details.
[Drug Interactions]
Cardiogenic shock. Sick sinus syndrome. Second and third degree atrioventricular block. Patients with unstable, decompensated heart failure (pulmonary edema, hypoperfusion, or hypotension), patients receiving continuous or intermittent inotropic therapy with beta-agonists. Symptomatic bradycardia or hypotension. This product should not be used in patients with suspected acute myocardial infarction with a heart rate <45 beats/min, a P-Q interval >0.24 seconds, or a systolic blood pressure <100 mmHg. Patients with heart failure indications whose supine systolic blood pressure is consistently below 100 mmHg should have their suitability for this product reassessed before starting treatment. Patients with severe peripheral vascular disease who are at risk of gangrene. Patients with hypersensitivity to any component of this product or other beta-blockers.
[Specifications]
47.5mg x 28 tablets
[Dosage and Administration]
Oral, once daily, preferably in the morning. The tablets may be broken but not chewed or crushed. They should be taken with at least half a cup of liquid. Concomitant food intake does not affect bioavailability. Dosage should be individualized to avoid bradycardia. (See package insert for other details.)
[Adverse Reactions]
See package insert for details.
[Contraindications]
Cardiogenic shock. Sick sinus syndrome. Second- and third-degree atrioventricular block. Patients with unstable, decompensated heart failure (pulmonary edema, hypoperfusion, or hypotension), or those receiving continuous or intermittent inotropic therapy with beta-agonists. Symptomatic bradycardia or hypotension. This product should not be administered to patients with suspected acute myocardial infarction and a heart rate <45 beats/min, a P-Q interval >0.24 seconds, or a systolic blood pressure <100 mmHg. Patients with heart failure indications whose supine systolic blood pressure is less than 100 mmHg on multiple occasions should have their suitability for this product reassessed before starting treatment. Patients with severe peripheral vascular disease with a risk of gangrene. Patients who are allergic to any component of this product or other beta-blockers.
